TABLE I.

Clinical Characteristics of Localized Prostate Cancer Patients

	Controls (NED)	Cases (CR)	P-value
	n = 154	n = 33
Age
Median	64	66	0.056
IQR	56–69	62–71
Range	44–82	45–76
PSA before surgery (ng/ml)
Median	7.16	7.4	0.17
IQR	4.81–10.40	5.60–13.0
Range	1.1–120	2.2–65.80
Pathologic Gleason score
≤6	56 (36)	5 (15)	0.01
(3 + 4) or (2 + 5)	60 (39)	11 (33)
(4 + 3) or (5 + 2)	14 (9)	5 (15)
8–10	24 (16)	12 (36)
Surgical margin status
Negative	119 (77)	24 (73)	0.651
Positive	35 (23)	9 (27)
Race/ethnicity
Non-Hispanic White	137 (89)	29 (88)	0.255
Hispanic	12 (8)	1 (3)
African-American	4 (3)	2 (6)
Asian/PI	1 (1)	1 (3)
Clinical stage
cT1	105 (68)	17 (52)	0.089
cT2	48 (31)	15 (45)
cT3	1 (1)	1 (3)
Pathologic stage
T2a	10 (6)	3 (9)	0.819
T2b	9 (6)	1 (3)
T2c	134 (87)	29 (88)
T2 with unknown laterality	1	0
Prostatectomy year
07/1988–07/1994	56 (37)	18 (55)	0.093
07/1994–03/2005	90 (59)	13 (39)
03/2005–06/2008	6 (4)	2 (6)
D’Amico risk groups (Those with available clinical data: Gleason, stage, PSA)
Low	50 (40)	2 (8)	<0.001
Intermediate	60 (48)	11 (42)
High	15 (12)	13 (50)
Neoadjuvant hormonal therapy
No	148 (96)	25 (76)	0.001
Yes	6 (4)	8 (24)
Radiation therapy
No	135 (88)	26 (79)	0.177
Yes	19 (12)	7 (21)
Adjuvant hormone therapy
No	151 (98)	33 (100)
Yes	3 (2)	0 (0)
Median follow-up time (IQR)	9.55 (6.61–15.25)	5.83 (4.18–8.69)

NED, patients with “no evidence of disease” after radical prostatectomy; CR, patients with clinical recurrence after radical prostatectomy.